Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

ABSTRACT:

Introduction

Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive target in B-cell malignancy and is the subject of several therapeutic strategies. The anti-CD19, humanized, monoclonal antibody tafasitamab (MOR208) has an engineered, modified Fc region with increased affinity for Fcγ receptors, leading to increased cytotoxicity via natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis) in a promising approach.

Areas covered

The development of tafasitamab is reviewed, together with the pharmacokinetics and clinical experi

SUBMITTER: Salles G 

PROVIDER: S-EPMC8363059 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature